MCID: LMT001
MIFTS: 47

Limited Scleroderma

Categories: Bone diseases, Nephrological diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Limited Scleroderma

MalaCards integrated aliases for Limited Scleroderma:

Name: Limited Scleroderma 12 15 17
Limited Cutaneous Systemic Sclerosis 12 52 58
Systemic Sclerosis Sine Scleroderma 52 58 71
Limited Cutaneous Systemic Scleroderma 52 58
Limited Systemic Sclerosis 52 58
Scleroderma, Limited 43 71
Progressive Systemic Sclerosis Sine Scleroderma 52
Systemic Sclerosis, Limited 12
Scleroderma, Sine 52
Crest Syndrome 71

Characteristics:

Orphanet epidemiological data:

58
limited cutaneous systemic sclerosis
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult; Age of death: adult;
limited systemic sclerosis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:1577
MeSH 43 D045745
SNOMED-CT 67 299276009
ICD10 via Orphanet 33 M34.0 M34.1
UMLS 71 C0206138 C0748540 C1290138

Summaries for Limited Scleroderma

NIH Rare Diseases : 52 Limited cutaneous systemic sclerosis is a subtype of systemic sclerosis characterized by the association of Raynaud's phenomenon and skin fibrosis on the hands, face, feet and forearms. The exact cause of limited cutaneous systemic sclerosis is unknown, but likely originates from an autoimmune reaction which leads to overproduction of collagen. In some cases, the condition is associated with exposure to certain chemicals. Management is aimed at treating the symptoms present in each affected individual.

MalaCards based summary : Limited Scleroderma, also known as limited cutaneous systemic sclerosis, is related to crest syndrome and scleroderma, familial progressive. An important gene associated with Limited Scleroderma is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are IL12-mediated signaling events and Innate Lymphoid Cells Differentiation. The drugs Ropivacaine and Anesthetics have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and lung, and related phenotypes are hypopigmented skin patches and autoimmunity

Related Diseases for Limited Scleroderma

Diseases related to Limited Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 crest syndrome 32.6 TOP1 SNRNP70 FBL EXOSC10 CENPS CENPC
2 scleroderma, familial progressive 31.2 TOP1 FBL CENPB CCN2
3 systemic scleroderma 30.9 TSSK1B TRIM21 TOP1 SNRNP70 IRF5 FBL
4 juvenile rheumatoid arthritis 30.8 IL2RA IL2 HLA-DRB1
5 diffuse cutaneous systemic sclerosis 30.8 IRF5 HLA-DRB1 CCR6 CCN2 CAV1
6 lupus erythematosus 30.6 TRIM21 SNRNP70 IRF5 HLA-DRB1
7 raynaud disease 30.5 TRIM21 TOP1 SNRNP70 EXOSC10 CENPB
8 collagen disease 30.4 TRIM21 SNRNP70 CCR6
9 gastric antral vascular ectasia 30.4 TOP1 CENPS
10 telangiectasis 30.3 TRIM21 TOP1 SNRNP70 FBL EXOSC10 CENPS
11 connective tissue disease 30.2 TOP1 SNRNP70 HLA-DRB1 FBL CENPC CENPB
12 diffuse scleroderma 30.1 TSSK1B TRIM21 TOP1 SNRNP70 FBL EXOSC10
13 autoimmune disease 30.0 TRIM21 IRF5 IL2RA IL2 HLA-DRB1 FBL
14 systemic lupus erythematosus 29.9 TRIM21 SNRNP70 KIAA0319L IRF5 IL2RA IL2
15 reynolds syndrome 11.5
16 telangiectasia, hereditary hemorrhagic, type 4 11.3
17 conjunctival vascular disease 10.6 TRIM21 TOP1
18 tuberculoid leprosy 10.6 IL2RA IL2 CCR6
19 red cell aplasia 10.6 IL2RA IL2 HLA-DRB1
20 recurrent respiratory papillomatosis 10.6 IL2 HLA-DRB1
21 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.6 IL2RA IL2 CCR6
22 pars planitis 10.6 IL2 HLA-DRB1 CCR6
23 pure red-cell aplasia 10.6 IL2RA IL2 HLA-DRB1
24 posterior uveitis 10.6 IL2RA IL2 CCR6
25 autoimmune gastritis 10.6 IL2 HLA-DRB1 CCR6
26 hypersensitivity reaction type iv disease 10.6 IL2 HLA-DRB1 CCR6
27 autoimmune disease of gastrointestinal tract 10.6 IL2 HLA-DRB1 CCR6
28 herpes zoster 10.6 IL2 HLA-DRB1 CCR6
29 pulmonary sarcoidosis 10.6 IL2RA IL2 CCR6
30 exanthem 10.6 TRIM21 IL2 CCR6
31 refractory hairy cell leukemia 10.6 IL2RA HLA-DRB1
32 pulmonary arterial hypertension associated with congenital heart disease 10.6 CCN2 CAV1
33 facial hemiatrophy 10.6 SNRNP70 EXOSC10
34 intermediate uveitis 10.6 IL2RA IL2 HLA-DRB1 CCR6
35 autoimmune disease of endocrine system 10.5 IL2RA IL2 HLA-DRB1 CCR6
36 salivary gland disease 10.5 TRIM21 IL2 CCR6
37 leprosy 3 10.5 IL2 HLA-DRB1 CCR6
38 mumps 10.5 IL2RA IL2 HLA-DRB1
39 sarcoidosis 1 10.5 IL2RA IL2 HLA-DRB1 CCR6
40 rubella 10.5 IL2RA IL2 HLA-DRB1
41 crohn's disease 10.5 IRF5 IL2 HLA-DRB1 CCR6
42 trochlear nerve disease 10.5 TRIM21 HLA-DRB1
43 syndromic x-linked intellectual disability cabezas type 10.5 TOP1 SNRNP70 EXOSC10 CCN2
44 autoimmune disease of exocrine system 10.5 TRIM21 SNRNP70 IRF5 CCR6
45 adult t-cell leukemia 10.5 IL2RA IL2 CCR6
46 ulcerative colitis 10.5 IRF5 IL2 HLA-DRB1 CCR6
47 childhood type dermatomyositis 10.5 TRIM21 SNRNP70 EXOSC10 CCR6
48 colitis 10.5 IRF5 IL2 HLA-DRB1 CCR6
49 behcet syndrome 10.5 IL2RA IL2 HLA-DRB1 CCR6
50 vernal conjunctivitis 10.5 IL2RA CCR6

Graphical network of the top 20 diseases related to Limited Scleroderma:



Diseases related to Limited Scleroderma

Symptoms & Phenotypes for Limited Scleroderma

Human phenotypes related to Limited Scleroderma:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypopigmented skin patches 58 31 hallmark (90%) Very frequent (99-80%) HP:0001053
2 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
3 narrow foramen obturatorium 58 31 hallmark (90%) Very frequent (99-80%) HP:0100958
4 gastroesophageal reflux 58 31 frequent (33%) Frequent (79-30%) HP:0002020
5 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
6 telangiectasia of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0100585
7 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
8 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
9 mucosal telangiectasiae 58 31 frequent (33%) Frequent (79-30%) HP:0100579
10 pulmonary arterial hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002092
11 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
12 joint contracture of the hand 58 31 occasional (7.5%) Occasional (29-5%) HP:0009473
13 contractures involving the joints of the feet 58 31 occasional (7.5%) Occasional (29-5%) HP:0008366
14 abnormality of skin pigmentation 58 Very frequent (99-80%)
15 abnormality of the skin 58 Very frequent (99-80%)

Drugs & Therapeutics for Limited Scleroderma

Drugs for Limited Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2 Anesthetics Phase 4
3 Anesthetics, Local Phase 4
4
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
5
Sodium citrate Approved, Investigational Phase 3 68-04-2
6
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
7
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
8 Sodium Channel Blockers Phase 2, Phase 3
9 Pharmaceutical Solutions Phase 2, Phase 3
10 Anti-Arrhythmia Agents Phase 2, Phase 3
11 Diuretics, Potassium Sparing Phase 2, Phase 3
12 Citrate Phase 3
13 Phosphodiesterase 5 Inhibitors Phase 3
14 Phosphodiesterase Inhibitors Phase 3
15 Chelating Agents Phase 3
16 Vasodilator Agents Phase 3
17 Sildenafil Citrate Phase 3 171599-83-0
18 Calcium, Dietary Phase 3
19 Anticoagulants Phase 3
20
Calcium Nutraceutical Phase 3 7440-70-2 271
21
Treprostinil Approved, Investigational Phase 2 81846-19-7 6918140 54786
22
Epoprostenol Approved Phase 2 35121-78-9, 61849-14-7 5282411 5280427
23 Tezosentan Investigational Phase 2 180384-57-0
24 Ifetroban Investigational Phase 2 143443-90-7
25 Antihypertensive Agents Phase 2
26 Platelet Aggregation Inhibitors Phase 2
27
Epinephrine Approved, Vet_approved 51-43-4 5816
28
Racepinephrine Approved 329-65-7 838
29
Nitric Oxide Approved 10102-43-9 145068
30 Analgesics
31 Epinephryl borate
32 Analgesics, Opioid

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Intérêt du TFP (Transversalis Fascia Plane) Bloc échoguidé Pour l'analgésie du prélèvement Osseux de crête Iliaque Completed NCT02398474 Phase 4 TFP block ropivacaine;ropivacaine infiltration of the iliac crest bone
2 Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
3 Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
4 Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
5 DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
6 Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study With P144 Topical Adminsitration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00781053 Phase 2 P144 cream
7 Phase II, Multicenter, Randomized, Double-blind, Intraindividually Placebo Controlled Clinical Trial, to Evaluate Efficacy and Safety of p144 Topical Administration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00574613 Phase 2 P144;placebo
8 A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Recruiting NCT03919799 Phase 2 KD025;Placebo
9 A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH) Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
10 Multicentre, Placebo-Controlled, Multi-Dosis, Phase I Clinical Trial to Evaluate the Tolerability and Bioavailability of TGF β1 Inhibitor Peptide 144 After Topical Administration in Healthy Volunteers. Completed NCT00656825 Phase 1 P144 cream;P144 cream;P144 cream;Placebo
11 A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA Trial Recruiting NCT03145298 Phase 1
12 Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients Active, not recruiting NCT01655836 Phase 1
13 Comparative Clinical Study of the Prevention of the Reduction of Alveolar Crest by Alveoli Filling With an Injectable Calcium Phosphate After Extraction of Mandibular Molar or Pre Molar Unknown status NCT00740311
14 A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma Completed NCT01881529
15 A Multicenter, Prospective Cohort Study Using Nailfold VideoCAPillaroscopy(NVC) and Other Factors to Determine the Risk of Developing Digital Ulceration in Patients With Systemic Sclerosis (SSc) Completed NCT01377090
16 The Analgesic Efficacy of the Transversalis Fascia Plane Block in Iliac Crest Bone Graft Harvesting Completed NCT01133730 Active treatment;Placebo Arm
17 A Prospective Pilot Study on the Performance of The Plexur P™ Bone Void Filler Completed NCT00837473
18 Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. Completed NCT03211325
19 Metabolomic Analysis of Systemic Sclerosis Recruiting NCT02298777
20 A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis Active, not recruiting NCT03889509
21 Localized Effects of Photobiomodulation and Exogenous Nitric Oxide on CREST Patients Calcinosis Cutis & Raynaud Phenomenon Not yet recruiting NCT03972566 INOMAX
22 A Multicenter, Prospective, Longitudinal Study to Evaluate Gastrointestinal Function and Clinical and Molecular Biomarkers in Subjects With Early and Late Diffuse Cutaneous Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis, and Healthy Volunteers Withdrawn NCT02531009

Search NIH Clinical Center for Limited Scleroderma

Cochrane evidence based reviews: scleroderma, limited

Genetic Tests for Limited Scleroderma

Anatomical Context for Limited Scleroderma

MalaCards organs/tissues related to Limited Scleroderma:

40
Skin, Bone, Lung, Endothelial, Prostate, Thyroid, T Cells

Publications for Limited Scleroderma

Articles related to Limited Scleroderma:

(show top 50) (show all 223)
# Title Authors PMID Year
1
Galectin-1 and Galectin-3 Expression in Lesional Skin of Patients With Systemic Sclerosis-Association With Disease Severity. 61
32501939 2020
2
Systemic Sclerosis Sine Scleroderma With Pulmonary Arterial Hypertension in a 3-Year-Old Girl. 61
32269136 2020
3
Pulmonary nodular and cystic light chain deposition disease: A retrospective review of 10 cases. 61
32217287 2020
4
Calcinosis Cutis as the Initial Manifestation of Limited Scleroderma. 61
31985726 2020
5
Pauci-Immune Necrotizing Glomerulonephritis as a Manifestation of Systemic Sclerosis Sine Scleroderma. 61
31789998 2019
6
Periostin is induced by IL-4/IL-13 in dermal fibroblasts and promotes RhoA/ROCK pathway-mediated TGF-β1 secretion in abnormal scar formation. 61
31066603 2019
7
The evaluation of a home-based program for hands in patients with systemic sclerosis. 61
29198478 2019
8
Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. 61
30535994 2019
9
Chronic Eroded Perianal Plaque in a Patient with Limited Systemic Scleroderma. 61
31782710 2019
10
Involvement of Periostin in Skin Function and the Pathogenesis of Skin Diseases. 61
31037628 2019
11
Connective Tissue Disease: Current Concepts. 61
30466687 2019
12
Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach. 61
29655520 2018
13
Anti-RO 52-positive systemic sclerosis sine scleroderma with multisystem involvement and recurrent vasculitis. 61
30073982 2018
14
Improving life expectancy of patients with scleroderma: results from the South Australian Scleroderma Register. 61
29573101 2018
15
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. 61
29678941 2018
16
Systemic Sclerosis Sine Scleroderma in Mexican Patients. Case Reports. 61
28065485 2018
17
[RHEOLOGICAL PROPERTIES OF BLOOD SERUM AT SYSTEMIC SCLEROSIS]. 61
29697389 2018
18
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast. 61
30013378 2018
19
Periostin in the pathogenesis of skin diseases. 61
28916993 2017
20
Cutaneous calcinosis in a patient with limited scleroderma: CREST Syndrome. 61
29308290 2017
21
Upper gastrointestinal bleeding (watermelon stomach) in a patient with limited scleroderma (CREST syndrome). 61
27353193 2017
22
Choroidal and central foveal thickness in patients with scleroderma and its systemic associations. 61
27864836 2017
23
[Research of systemic sclerosis sine scleroderma]. 61
28870043 2017
24
Systemic sclerosis sine scleroderma. 61
29068586 2017
25
The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 61
28426903 2017
26
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. 61
28671485 2017
27
Scleroderma Induced by Pembrolizumab: A Case Series. 61
28599746 2017
28
Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature. 61
28440561 2017
29
Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key? 61
27340761 2017
30
Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension. 61
27052360 2016
31
Comparison of the clinical utility of the Elia CTD Screen to indirect immunofluorescence on Hep-2 cells. 61
26677892 2016
32
Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma. 61
26714268 2016
33
Fibrillary glomerulonephritis associated with limited scleroderma: a case report. 61
26709524 2016
34
Systemic sclerosis - a multi-purpose use of ultrasound: Editorial comment on: G. Pracoń, M. Płaza, M. Walentowska-Janowicz, I. Sudoł-Szopińska The value of ultrasound in the diagnosis of limited scleroderma - a case report. 61
27104009 2016
35
Polymyositis and the Spectrum of Scleroderma Disorders. 61
30755854 2016
36
Development of systemic sclerosis in patients with autoimmune hepatitis: an emerging overlap syndrome. 61
27458514 2016
37
A Unique Presentation of Anti-RNA Polymerase III Positive Systemic Sclerosis Sine Scleroderma. 61
27559487 2016
38
The value of ultrasound in the diagnosis of limited scleroderma - a case report. 61
26675049 2015
39
Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma. 61
26242276 2015
40
Systemic sclerosis sine scleroderma: a case report of anterior uveitis. 61
26150271 2015
41
Multiple intracerebral hemorrhages in a patient with systemic sclerosis sine scleroderma. 61
24993862 2015
42
[Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil]. 61
25559063 2015
43
Osteonecrosis of multiple joints in a patient with limited scleroderma/CREST syndrome. 61
25807102 2015
44
[Usefulness of gastric emptying scintigraphy for the evaluation and management of scleroderma related gastroparesis]. 61
26076515 2015
45
Digital Ulcers, Systemic Sclerosis Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy. 61
26223094 2015
46
Systemic Sclerosis Sine Scleroderma. 61
26259425 2014
47
Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. 61
25274885 2014
48
Systemic sclerosis sine scleroderma and limited cutaneous systemic sclerosis: similarities and differences. 61
24776173 2014
49
[Diffuse interstitial pneumonia revealing systemic sclerosis sine scleroderma]. 61
25775296 2014
50
Improved survival in limited scleroderma-related pulmonary artery hypertension. 61
23361526 2014

Variations for Limited Scleroderma

Expression for Limited Scleroderma

Search GEO for disease gene expression data for Limited Scleroderma.

Pathways for Limited Scleroderma

Pathways related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.38 IL2RA IL2 HLA-DRB1
2 11.03 IL2RA IL2 CCR6
3 10.25 IL2RA IL2 HLA-DRB1

GO Terms for Limited Scleroderma

Cellular components related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.63 TOP1 FBL CENPS CENPC CENPB CENPA
2 chromosome, centromeric region GO:0000775 9.56 CENPS CENPC CENPB CENPA
3 condensed chromosome kinetochore GO:0000777 9.54 CENPS CENPC CENPA
4 condensed nuclear chromosome kinetochore GO:0000778 9.32 CENPC CENPA
5 condensed nuclear chromosome, centromeric region GO:0000780 9.13 CENPC CENPB CENPA
6 nuclear pericentric heterochromatin GO:0031618 8.8 CENPC CENPB CENPA

Biological processes related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 9.5 TRIM21 IRF5 HLA-DRB1
2 regulation of regulatory T cell differentiation GO:0045589 9.43 IL2RA IL2
3 interleukin-2-mediated signaling pathway GO:0038110 9.4 IL2RA IL2
4 positive regulation of viral entry into host cell GO:0046598 9.37 TRIM21 HLA-DRB1
5 CENP-A containing nucleosome assembly GO:0034080 9.33 CENPS CENPC CENPA
6 negative regulation of lymphocyte proliferation GO:0050672 9.26 IL2RA IL2
7 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2RA IL2
8 kinetochore assembly GO:0051382 8.8 CENPS CENPC CENPA

Molecular functions related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 centromeric DNA binding GO:0019237 8.62 CENPC CENPB

Sources for Limited Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....